CTKB stock icon

Cytek Biosciences

6.47 USD
-0.07
1.07%
At close Dec 6, 4:00 PM EST
After hours
6.47
+0.00
0.00%
1 day
-1.07%
5 days
-0.46%
1 month
-12.57%
3 months
22.08%
6 months
8.38%
Year to date
-27.06%
1 year
-11.61%
5 years
-65.51%
10 years
-65.51%
 

About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Employees: 645

0
Funds holding %
of 6,794 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

103% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 32

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

6% more funds holding

Funds holding: 128 [Q2] → 136 (+8) [Q3]

3% less capital invested

Capital invested by funds: $430M [Q2] → $415M (-$14.6M) [Q3]

1.7% less ownership

Funds ownership: 58.7% [Q2] → 57.01% (-1.7%) [Q3]

60% less call options, than puts

Call options by funds: $2K | Put options by funds: $5K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$8.50
31%
upside
Avg. target
$8.50
31%
upside
High target
$8.50
31%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Piper Sandler
David Westenberg
50% 1-year accuracy
5 / 10 met price target
31%upside
$8.50
Overweight
Maintained
11 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference in New York, NY.
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
Neutral
GlobeNewsWire
2 weeks ago
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program.
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
Neutral
GlobeNewsWire
1 month ago
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system.
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
Neutral
Seeking Alpha
1 month ago
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call.
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
Neutral
GlobeNewsWire
2 months ago
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Neutral
GlobeNewsWire
2 months ago
Cytek Announces Resignation of Chief Operating Officer Chris Williams
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure.
Cytek Announces Resignation of Chief Operating Officer Chris Williams
Neutral
GlobeNewsWire
3 months ago
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification.
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Neutral
Seeking Alpha
3 months ago
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™